ArticleNPJ precision oncology2018
Recent advances in precision oncology research.
Article in NPJ precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Genetic association studies in critically ill patients: a systematic review.EBioMedicine · 2025Pooled it
- Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Pooled it
- Artificial intelligence and extracellular vesicles in oncology: towards tumor diagnosis, prediction, and therapy.Drug delivery · 2026Review
- Review
- Integrating transcriptomic data and artificial intelligence to personalize curative treatments for head and neck cancer patients.NPJ precision oncology · 2026Review
- Integrating liquid biopsy and mutational signatures to advance precision oncology.NPJ precision oncology · 2026Review
- Current Bioinformatics Tools in Precision Oncology.MedComm · 2025Review
- Case Report: Triple-negative breast cancer with brain and meningeal metastases exhibits spatiotemporal heterogeneity in terms of HER2 expression.Frontiers in oncology · 2025Article
- Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice.Journal of pharmacokinetics and pharmacodynamics · 2024Review
- The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options.Frontiers in oncology · 2024Review
- The roots of (in)equity in precision medicine: gaps in the discourse.Personalized medicine · 2024Article
- Article
- Consensus Statements on Precision Oncology in the China Greater Bay Area.JCO precision oncology · 2023Article
- Cost Analysis of a Digital Multimodal Cancer Prehabilitation.Current oncology (Toronto, Ont.) · 2022Article
- A Survey on Deep Learning for Precision Oncology.Diagnostics (Basel, Switzerland) · 2022Review
- Article
- Mechanism of activation and the rewired network: New drug design concepts.Medicinal research reviews · 2022Review
- An overview of machine learning methods for monotherapy drug response prediction.Briefings in bioinformatics · 2022Article
- Fatalism, distrust, and breast cancer treatment refusal in Ghana.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.